Detailed narrative
Core Test Performance and Strategic Focus
DecisionDx-Melanoma delivered 10,280 test reports in Q2 FY26, representing 3% year-over-year growth, and management reaffirmed expectations for mid- to high single-digit volume growth for the full year. TissueCypher reported 14,988 test reports, a robust 63% year-over-year increase, with full-year volume growth projected to trend towards 50%-52%. The commercial team is strategically adapting its customer engagement model to support three key products (Melanoma, SCC, AdvanceAD-Tx) within the same customer call, which temporarily moderated sequential melanoma growth but is viewed as a deliberate investment for long-term business expansion.
AdvanceAD-Tx Progress and Reimbursement Outlook
The AdvanceAD-Tx test garnered over 1,000 orders in Q2 FY26 and received the Genomics Innovation Award. A new independent real-world clinical utility study demonstrated that 97.8% of patients were initiated on molecularly concordant systemic therapy after AdvanceAD-Tx testing, a significant improvement from 54.3% at baseline. Furthermore, a panel unanimously voted 21-0 to crosswalk AdvanceAD-Tx to an existing code with a rate of $3,675, which management views as a strong benchmark for future commercial payer negotiations and a step towards a full commercial launch.
Clinical Evidence and Regulatory Milestones
A prospective multicenter study published in Q2 FY26 demonstrated that DecisionDx-Melanoma outperformed the Melanoma Institute Australia Nomogram in identifying patients at low and high risk of sentinel lymph node positivity. Low-risk patients identified by DecisionDx-Melanoma had an observed sentinel lymph node positivity rate of just 2.6%, well below the NCCN's 5% threshold for considering avoiding a biopsy. For DecisionDx-SCC, volumes saw a resurgence, attributed to existing customers recognizing its clinical value and increased promotional time from the sales force.
Pipeline Development and Future Initiatives
The company continues to advance its pipeline, including the Previse GI (Esopredict) tissue-based assay, which is now available as a reflex test for TissueCypher in cases where a TissueCypher result cannot be obtained. Development is also underway for a cell collection device, with updates expected in the first half of 2027. Management also indicated potential FDA clearance or approval for an unspecified asset later in 2026 or early 2027, leveraging its breakthrough device designation.
Financial Flexibility and Capital Allocation
Castle Biosciences maintains a robust balance sheet with $266.8 million in cash, cash equivalents, and marketable investment securities as of June 30, 2026. This financial flexibility supports continued investment in growth initiatives, including commercial resources, evidence development, pipeline advancement, and laboratory capacity, while maintaining a disciplined approach to capital allocation. The company expects to achieve positive adjusted EBITDA for the third and fourth quarters of 2026, as well as for the full years 2026 and 2027.